South Korea approves Phase 2/3 trials of Celltrion’s COVID-19 antibody drug

South Korea said on Thursday it has approved Celltrion Inc’s experimental COVID-19 treatment for Phase 2/3 clinical trials, as the firm plans to seek an emergency use authorization for the antibody …